Houston – November 05, 2026 -- ImmunoGenesis has published two papers reporting nonclinical evidence that its STING agonist IMGS-203 remodels the tumor microenvironment and can be combined with the company's cytotoxic dual-specific PD-L1/PD-L2 antibody. The clinical-stage biotech plans to take IMGS-203 into clinical development first in recurrent glioblastoma (GBM).
IMGS-203 reduces immunosuppressive cells and improves survival in tumor models
Nonclinical studies show that local administration of IMGS-203 remodels the tumor microenvironment (TME) and reduces immunosuppressive myeloid cell populations. It also enhances T-cell activation and improves survival in tumor models.
GBM is a highly immunosuppressive, myeloid-rich tumor in which conventional immune checkpoint inhibitors have shown limited efficacy as monotherapy.
STING activation raises PD-L1 and PD-L2 expression, opening a combination path
STING activation induces PD-L1 and PD-L2 expression. ImmunoGenesis sees this as an opening to boost antitumor activity by pairing IMGS-203 with its cytotoxic dual-specific PD-L1/PD-L2 antibody.
IND-enabling studies are in the final stretch ahead of GBM trials
Chief Scientific Officer Federica Pericle said the company is completing IND-enabling studies. She added that local STING activation could overcome the immunosuppressive TME in GBM. CEO James Barlow said the company is focused on moving IMGS-203 into the clinic for GBM patients.
Two 2026 papers document the mechanism
Salameh et al. in the Journal of Experimental and Clinical Cancer Research reports that STING pathway activation can overcome immune exclusion by promoting TME remodeling and immune cell recruitment. The study also finds that STING agonism sensitizes endothelial cells to a cytotoxic anti-PD-L1/L2 antibody.
Boda et al. in Frontiers in Immunology reviews data showing how STING activation can reconfigure the TME to produce potent antitumor effects.